阿魏酸
神经保护
化学
HDAC6型
药理学
褪黑素
神经毒性
抗氧化剂
体外
组蛋白脱乙酰基酶
体内
生物化学
内科学
毒性
组蛋白
有机化学
医学
生物
生物技术
基因
作者
Feng He,C. James Chou,Matthias Scheiner,Eleonora Poeta,Natalia Yuan Chen,Sandra Gunesch,Matthias Hoffmann,Christoph Sotriffer,Barbara Monti,Tangui Maurice,Michael W. Decker
标识
DOI:10.1021/acs.jmedchem.0c01940
摘要
The structures of melatonin and ferulic acid were merged into tertiary amide-based histone deacetylase 6 (HDAC6) inhibitors to develop multi-target-directed inhibitors for neurodegenerative diseases to incorporate antioxidant effects without losing affinity and selectivity at HDAC6. Structure-activity relationships led to compound 10b as a hybrid molecule showing pronounced and selective inhibition of HDAC6 (IC50 = 30.7 nM, > 25-fold selectivity over other subtypes). This compound shows comparable DPPH radical scavenging ability to ferulic acid, comparable ORAC value to melatonin and comparable Cu 2+ chelating ability to EDTA. It also lacks neurotoxicity on HT-22 cells, exhibits a pronounced immunomodulatory effect, and is active in vivo showing significantly higher efficacy in an AD mouse model to prevent both Aβ25−35-induced spatial working and long-term memory dysfunction at lower dose (0.3 mg/kg) compared to positive control HDAC6 inhibitor ACY1215 and an equimolar mixture of the three entities ACY1215, melatonin and ferulic acid, suggesting potentially disease-modifying properties.
科研通智能强力驱动
Strongly Powered by AbleSci AI